CytomX Therapeutics to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
10 August 2023 - 10:05PM
CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of
conditionally activated, localized biologics, today announced that
Sean McCarthy, D.Phil., chief executive officer and chairman,
will present at the H.C. Wainwright Immune Cell Engager
Virtual Conference on Thursday, August 17 at 9:00 a.m. ET.
A live webcast of the fireside chat will be available on the
Events and Presentations page of CytomX’s website at
www.cytomx.com. In addition, management will be available for
one-on-one meetings with investors who are registered to attend the
conferences.
About CytomX TherapeuticsCytomX is a
clinical-stage, oncology-focused biopharmaceutical company focused
on developing novel conditionally activated biologics localized to
the tumor microenvironment. By pioneering a novel class of
conditionally activated biologics, powered by its
Probody® technology platform, CytomX’s goal is to transcend
the limits of current cancer treatments. CytomX’s robust and
differentiated pipeline comprises therapeutic candidates across
multiple treatment modalities including antibody-drug conjugates
(“ADCs”), T-cell engaging bispecific antibodies, and immune
modulators such as cytokines and checkpoint inhibitors. CX-2029 is
an investigational conditionally ADCs directed toward CD71.
CytomX’s clinical pipeline also includes cancer immunotherapeutic
candidates against validated targets such as the CTLA-4-targeting
Probody therapeutic BMS-986288, partnered with Bristol Myers
Squibb, as well as CX-904, a conditionally activated
T-cell-engaging bispecific antibody targeting the epidermal growth
factor receptor (EGFR) on tumor cells and the CD3 receptor on T
cells, which is partnered with Amgen. In addition, CytomX has a
diverse preclinical portfolio of wholly-owned assets including
CX-801, an interferon alpha-2b Probody cytokine that has broad
potential applicability in traditionally immuno-oncology sensitive
as well as insensitive (cold) tumors and CX-2051, a conditionally
activated ADC directed toward EpCAM, with potential applicability
across multiple EpCAM-expressing epithelial cancers. CytomX has
also established strategic collaborations with multiple leaders in
oncology, including Amgen, Astellas, Bristol Myers Squibb,
Regeneron and Moderna. For more information about CytomX and how it
is working to make conditionally activated treatments the new
standard-of-care in the fight against cancer, visit www.cytomx.com
and follow us on LinkedIn and Twitter.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chris OgdenSVP,
Finance and Accounting cogden@cytomx.com(317) 767-4764
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
CytomX Therapeutics (NASDAQ:CTMX)
Historical Stock Chart
Von Mai 2023 bis Mai 2024